Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher M Rubino

Showing results (1-10 of 68) with videos related to

Pageof 7
Sort By:
Antimicrobial Agents and Chemotherapy|August 16, 2021
Population Pharmacokinetics of Rezafungin in Patients with Fungal InfectionsChristopher M Rubino, Shawn Flanagan
Paediatric Drugs|December 7, 2007
Optimizing therapy with antibacterial agents: use of pharmacokinetic-pharmacodynamic principles in pediatricsChristopher M Rubino, John S Bradley
Clinical Pharmacology : Advances and Applications|February 6, 2015
Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteersStephen J Farr, Cynthia Y Robinson, Christopher M Rubino
Current Opinion in Pharmacology|November 21, 2017
Ensuring quality pharmacokinetic analyses in antimicrobial drug development programsElizabeth A Lakota, Justin C Bader, Christopher M Rubino
Journal of Opioid Management|November 5, 2015
A pharmacokinetic evaluation of single and multiple doses of extended-release hydrocodone bitartrate in subjects experiencing surgical or osteoarthritic painCynthia Y Robinson, Christopher M Rubino, Stephen J Farr
Antimicrobial Agents and Chemotherapy|March 21, 2018
Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 DataElizabeth A Lakota, Voon Ong, Shawn Flanagan, et al.
The Journal of Antimicrobial Chemotherapy|April 6, 2019
Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methodsLi Zhang, Wolfgang W Wicha, Sujata M Bhavnani, et al.
Journal of Clinical Pharmacology|December 15, 2017
Minimal Physiologically Based Pharmacokinetic and Drug-Drug-Disease Interaction Model of Rivaroxaban and Verapamil in Healthy and Renally Impaired SubjectsMohamed Ismail, Vincent H Lee, Christina R Chow, et al.
Antimicrobial Agents and Chemotherapy|May 6, 2015
Determination of appropriate weight-based cutoffs for empiric cefazolin dosing using data from a phase 1 pharmacokinetics and safety study of cefazolin administered for surgical prophylaxis in pediatric patients aged 10 to 12 yearsMichael L Schmitz, Jeffrey L Blumer, Wes Cetnarowski, et al.
Clinical Pharmacokinetics|May 31, 2013
Population pharmacokinetic analysis for hydrocodone following the administration of hydrocodone bitartrate extended-release capsulesMurad R Melhem, Christopher M Rubino, Stephen J Farr, et al.
Pageof 7

Showing results (1-10 of 68) with videos related to

Sort By:
Pageof 7
Antimicrobial Agents and Chemotherapy|August 16, 2021
Population Pharmacokinetics of Rezafungin in Patients with Fungal InfectionsChristopher M Rubino, Shawn Flanagan
Paediatric Drugs|December 7, 2007
Optimizing therapy with antibacterial agents: use of pharmacokinetic-pharmacodynamic principles in pediatricsChristopher M Rubino, John S Bradley
Clinical Pharmacology : Advances and Applications|February 6, 2015
Effects of food and alcohol on the pharmacokinetics of an oral, extended-release formulation of hydrocodone in healthy volunteersStephen J Farr, Cynthia Y Robinson, Christopher M Rubino
Current Opinion in Pharmacology|November 21, 2017
Ensuring quality pharmacokinetic analyses in antimicrobial drug development programsElizabeth A Lakota, Justin C Bader, Christopher M Rubino
Journal of Opioid Management|November 5, 2015
A pharmacokinetic evaluation of single and multiple doses of extended-release hydrocodone bitartrate in subjects experiencing surgical or osteoarthritic painCynthia Y Robinson, Christopher M Rubino, Stephen J Farr
Antimicrobial Agents and Chemotherapy|March 21, 2018
Population Pharmacokinetic Analyses for Rezafungin (CD101) Efficacy Using Phase 1 DataElizabeth A Lakota, Voon Ong, Shawn Flanagan, et al.
The Journal of Antimicrobial Chemotherapy|April 6, 2019
Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methodsLi Zhang, Wolfgang W Wicha, Sujata M Bhavnani, et al.
Journal of Clinical Pharmacology|December 15, 2017
Minimal Physiologically Based Pharmacokinetic and Drug-Drug-Disease Interaction Model of Rivaroxaban and Verapamil in Healthy and Renally Impaired SubjectsMohamed Ismail, Vincent H Lee, Christina R Chow, et al.
Antimicrobial Agents and Chemotherapy|May 6, 2015
Determination of appropriate weight-based cutoffs for empiric cefazolin dosing using data from a phase 1 pharmacokinetics and safety study of cefazolin administered for surgical prophylaxis in pediatric patients aged 10 to 12 yearsMichael L Schmitz, Jeffrey L Blumer, Wes Cetnarowski, et al.
Clinical Pharmacokinetics|May 31, 2013
Population pharmacokinetic analysis for hydrocodone following the administration of hydrocodone bitartrate extended-release capsulesMurad R Melhem, Christopher M Rubino, Stephen J Farr, et al.
Pageof 7